Blueprint Medicines Corporation (NASDAQ:BPMC) will be hosting a conference call at 8:30 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.blueprintmedicines.com
Earnings Expectation
Blueprint Medicines Corporation is reporting third quarter financial results on Thursday 29th October 2020, before market open.
According to analysts surveyed by Thomson Reuters, BPMC is expected to report 3Q20 income of $ 7.72 per share from revenue of $ 631.57 million.
For the full year, analysts anticipate top line of $ 635.65 million, while looking forward to income of $ 1.68 per share bottom line.
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies.
